Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07460375) titled 'A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors' on Feb. 26.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: LigaChem Biosciences, Inc.
Condition:
Advanced Solid Tumors
Intervention:
Drug: LCB02A
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: August 2026
Target Sample Size: 191
Countries of Recruitment:
United States
Canada
South Korea
Canada
South Korea
United States
To know more, visit https://clinicaltrial...